Literature DB >> 26556487

The effect of aortic stenosis on elderly hip fracture outcomes: A case control study.

Aakash Keswani1, Andrew Lovy2, Mian Khalid2, Ira Blaufarb2, Calin Moucha2, David Forsh2, Darwin Chen2.   

Abstract

INTRODUCTION: Aortic stenosis (AS) is an established predictor of perioperative complications following both cardiac and non-cardiac surgery. The purpose of this study was to evaluate the risk of mortality and perioperative complications among surgically treated hip fractures in elderly patients with moderate or severe AS compared to those without AS (negative controls).
MATERIALS AND METHODS: A retrospective case-controlled review (1:2) of elderly (≥65 years) surgically treated hip fractures from 2011 to 2015 with moderate/severe AS (according to American Heart Association criteria) was conducted. Postoperative complication rates, 30 days and 1 year mortality were reviewed.
RESULTS: Moderate/severe AS was identified in 65 hip fracture cases and compared to 129 negative controls. AS cases were significantly older with higher rates of coronary artery disease and atrial fibrillation (p<0.05). Rates of any 30-day perioperative complication (74% vs. 37%, p<0.001) and severe non-cardiac 30-day perioperative complication (52% vs. 26%, p=0.002) were significantly higher among AS cases compared to controls. Kaplan Meier estimates of 30-day mortality (14.7% vs. 4.2%, p<0.001) and 1-year mortality (46.8% vs. 14.1%, p<0.001) were significantly higher in AS cases compared to controls. Multivariate analysis of severe 30-day postoperative complications identified moderate/severe AS (OR 4.02, p=0.001), pulmonary disease (OR 7.36, p=0.002) and renal disease (OR 3.27, p=0.04) as independent predictors. Moderate/severe AS (OR 3.38, p=0.03), atrial fibrillation (OR 3.73, p=0.03) and renal disease (OR 4.44, p=0.02) were independent predictors of 30-day mortality. Moderate/severe AS (OR 5.79, p<0.001) and renal disease (OR 3.39, p=0.02) were independent predictors of 1-year mortality.
CONCLUSION: Aortic stenosis is associated with a significantly increased risk of perioperative complications, 30-day mortality and 1-year mortality in elderly patients undergoing surgical treatment of hip fractures.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Adverse event; Aortic stenosis; Elderly; Hip fracture; Mortality; Perioperative risk

Mesh:

Year:  2015        PMID: 26556487     DOI: 10.1016/j.injury.2015.10.015

Source DB:  PubMed          Journal:  Injury        ISSN: 0020-1383            Impact factor:   2.586


  5 in total

1.  TAVR in patients with hip fracture and severe aortic stenosis: how and when?

Authors:  Carlo Rostagno; Giorgia Falchetti; Andrea Carlo Rostagno; Alessio Mattesini
Journal:  Intern Emerg Med       Date:  2021-05-20       Impact factor: 3.397

2.  Outcome in elderly patients with aortic stenosis undergoing hip fracture surgery. Results may suggest a different postoperative strategy?

Authors:  Carlo Rostagno; Claudia Ranalli; Gianluca Polidori; Alessandro Cartei; Alberto Boccaccini; Adriano Peris
Journal:  Trauma Surg Acute Care Open       Date:  2019-01-12

3.  Severe aortic stenosis is associated with perioperative mortality in proximal femur fracture patients.

Authors:  Patrick K Cronin; Jeffrey J Olson; Mitchel B Harris; Michael J Weaver
Journal:  OTA Int       Date:  2020-05-05

4.  Hip Fracture Surgery in Severe Aortic Stenosis: A Study of Factors Affecting Mortality.

Authors:  Carlo Rostagno; Alessandro Cartei; Gaia Rubbieri; Alice Ceccofiglio; Roberto Civinini; Massimo Curcio; Gianluca Polidori; Alberto Boccaccini
Journal:  Clin Interv Aging       Date:  2022-08-04       Impact factor: 3.829

5.  Prediction of Early Postoperative Major Cardiac Events and In-Hospital Mortality in Elderly Hip Fracture Patients: The Role of Different Types of Preoperative Cardiac Abnormalities on Echocardiography Report.

Authors:  Xuepan Chen; Yuanchen Ma; Zhantao Deng; Qingtian Li; JunXing Liao; Qiujian Zheng
Journal:  Clin Interv Aging       Date:  2020-05-27       Impact factor: 4.458

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.